Bio-Rad initiated at Barclays

Bio-Rad initiated with an Equal Weight at Barclays. Barclays analyst Jack Meehan started Bio-Rad Laboratories with an Equal Weight rating and $345 price target. The analyst views the investment thesis and valuation as balanced at current share levels. He sees a lot of long-term opportunity at Bio-Rad, but also near-term challenges, including Diagnostics pricing.
https://thefly.com/landingPageNews.php?id=2785709